Peter Barrett
About Peter Barrett
Peter Barrett, PhD (age 72), is an independent director of Revvity (RVTY) serving since 2012; he chairs the Compensation & Benefits Committee and sits on the Nominating & Corporate Governance Committee. He is a Partner at Atlas Venture; previously co‑founded Celera Genomics (EVP/CBO) and held senior roles at The Perkin‑Elmer Corporation. He holds a BS in chemistry (UMass Lowell) and a PhD in analytical chemistry (Northeastern) .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| The Perkin‑Elmer Corporation | VP, Corporate Planning & Business Development; senior management roles | Prior to 2002 (dates per bio) | Expanded life sciences portfolio via licensing, partnerships, M&A |
| Celera Genomics | Co‑founder; EVP & Chief Business Officer | Through 2001 | Led alliances/M&A; Celera announced first successful human genome sequencing in 2001 |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Atlas Venture | Partner (Life Sciences) | Since 2002 | Early-stage life sciences VC; creation of multiple therapeutics/platform companies |
| Synlogic, Inc. (public) | Chairman of the Board | Current | Public company directorship; leadership of board |
| Obsidian Therapeutics (private) | Director | Current | Private company board |
| Larimar Therapeutics, Inc. (public) | Director | Until 2023 | Prior public company board |
| Harvard Business School | Executive Fellow; Chair, Key Advisory Board of the Blavatnik Fellowship program | Current | Academic/mentoring roles |
| Nucleate (non‑profit) | Board member | Current | Student-run non-profit for bio-innovators |
Board Governance
- Independence: The Board determined Dr. Barrett is independent under NYSE rules .
- Committees: Chair, Compensation & Benefits; Member, Nominating & Corporate Governance .
- Attendance & engagement: The Board met six times in FY2024; each director attended ≥75% of combined Board and committee meetings; all directors attended the 2024 annual meeting (virtual) .
- Board structure: 9 of 10 directors independent; Non‑Executive Chair; independent directors meet without management at each regularly scheduled meeting .
- Tenure: Director since 2012; Board matrix shows 13 years of service as of the 2025 proxy .
Fixed Compensation (Director)
| Component | Detail | Amount/Description |
|---|---|---|
| Annual cash retainer | Non‑employee director | $90,000 (paid quarterly) |
| Committee chair fee | Compensation & Benefits Committee Chair | $20,000 additional annual retainer |
| 2024 cash actually paid | Peter Barrett | $110,000 |
| Meeting fees | Not applicable | No per‑meeting fees disclosed |
2024 Director Compensation (as reported):
| Name | Fees Earned or Paid in Cash ($) | Stock Awards ($) | Total ($) |
|---|---|---|---|
| Peter Barrett, PhD | $110,000 | $224,933 | $334,933 |
Notes:
- 2024 Non‑employee director stock grant: 1,218 shares of common stock ($124,967 fair value); annual RSU grant: 977 RSUs ($99,967 fair value); grant date May 1, 2024; RSUs vest 100% at the next annual meeting (accelerated on death/disability/qualifying retirement or within 12 months post‑change‑in‑control) .
- As of Dec 29, 2024, each non‑employee director held 977 unvested RSUs; none held stock options .
Performance Compensation
- Directors at Revvity do not receive performance‑conditioned pay; equity awards are time‑based (common stock and RSUs), with RSUs vesting at the next annual meeting .
Other Directorships & Interlocks
- Current public boards: Synlogic, Inc. (Chairman) .
- Prior public boards: Larimar Therapeutics, Inc. (through 2023) .
- Compensation committee interlocks: None—no interlocking relationships reported for 2024 among Compensation & Benefits Committee members (Dr. Barrett, Dr. McMurry‑Heath, Dr. Witney, Ms. Witz) .
Expertise & Qualifications
- Three decades in life sciences as senior executive and institutional investor; strategic growth/M&A expertise; experience as board chair and director across public/private companies .
- Education: BS chemistry (UMass Lowell); PhD analytical chemistry (Northeastern) .
Equity Ownership
| Item | Detail |
|---|---|
| Beneficial ownership (2/14/2025) | 23,601 shares; less than 1% of class |
| Unvested RSUs (12/29/2024) | 977 RSUs |
| Ownership guidelines | Directors must hold ≥5x annual cash retainer ($450,000 for 2024); all directors were in compliance as of 2/14/2025 |
| Trading/hedging policy | Directors/employees prohibited from short sales and all derivative/hedging/monetization transactions. Officers may not pledge or hold shares in margin accounts |
Insider Transactions (Form 4) – FY2024–FY2025:
| Transaction Date | Type | Securities Transacted | Post-Transaction Holdings | Source |
|---|---|---|---|---|
| 2024-05-01 | A (Award) – Common Stock | 1,218 | 23,601 | https://www.sec.gov/Archives/edgar/data/31791/000095017024052076/0000950170-24-052076-index.htm |
| 2024-05-01 | A (Award) – Common Stock | 977 | 22,383 | https://www.sec.gov/Archives/edgar/data/31791/000095017024052076/0000950170-24-052076-index.htm |
| 2025-04-30 | A (Award) – Common Stock | 1,338 | 26,013 | https://www.sec.gov/Archives/edgar/data/31791/000095017025061820/0000950170-25-061820-index.htm |
| 2025-04-30 | A (Award) – Common Stock | 1,074 | 24,675 | https://www.sec.gov/Archives/edgar/data/31791/000095017025061820/0000950170-25-061820-index.htm |
Note: From Jan 1, 2023 through Nov 20, 2025, retrieved Form 4s show director equity awards only; no open‑market purchases (“P”) or sales (“S”) were found in the queried period (records above) .
Governance Assessment
- Strengths for investor confidence:
- Independence and long tenure with sector‑specific expertise; leadership as Compensation Chair and service on Nominating & Corporate Governance .
- Strong engagement: ≥75% attendance threshold met; Board met 6x in 2024; directors attend annual meetings; independent sessions each regular meeting .
- Alignment mechanisms: meaningful director equity; 5x retainer ownership guideline met; hedging/derivative bans enhance alignment .
- No compensation committee interlocks reported for 2024 ; broad shareholder support for say‑on‑pay (95.7% in 2024), reflecting positive governance sentiment .
- Watch items:
- Director equity retainer was increased by $25,000 for 2024 (to $225,000 total equity value for non‑chair directors), aligning with peers but contributing modestly to pay inflation risk; no changes for 2025 .
- Related‑party oversight: clear policy is in place and overseen by the Nominating & Corporate Governance Committee; monitor for any future transactions given Dr. Barrett’s extensive external affiliations; the policy outlines approval standards and annual review .
Related Policies and Structures (for context)
- Director Compensation program: cash plus equity; RSUs vest at next annual meeting; Non‑Executive Chair receives higher retainers .
- Board composition and leadership: Non‑Executive Chair; majority independent; majority voting in uncontested elections .
All citations: Revvity, Inc. 2025 DEF 14A (filed March 12, 2025) . Form 4 filings for Peter Barrett as cited above.